This study analyzed the antimicrobial resistance profiles and risk factors for carbapenem-resistant Acinetobacter baumannii (CRAB) in a tertiary hospital and developed a predictive model for infection control. Among 64 Acinetobacter baumannii isolates collected in 2024 from the First People's Hospital of Chuzhou, CRAB accounted for 40.63% (26/64), with sputum being the most common specimen source (85.94%) and the highest isolation rate observed in respiratory wards. CRAB exhibited significantly higher resistance to most antibiotics compared to carbapenem-sensitive strains (CSAB), except for polymyxin and tigecycline (P < 0.05). Multivariate analysis identified ≥3 underlying diseases, prior use of compound antibiotics, and tracheal intubation/incision as independent risk factors for CRAB infection. A nomogram prediction model constructed with R software demonstrated high predictive accuracy (C-index: 0.985). The findings highlight a concerning prevalence and multidrug resistance of CRAB in this setting, underscoring the need to enhance monitoring, early risk factor identification, and targeted interventions to reduce transmission and optimize antimicrobial stewardship.
HamidianM, NigroSJ. Emergence, molecular mechanisms and global spread of carbapenem-resistant Acinetobacter baumannii. Microb Genom, 2019; 5(10):e000306; doi: 10.1099/mgen.0.000306
2.
RamirezMS, BonomoRA, TolmaskyME. Carbapenemases: Transforming acinetobacter baumannii into a yet more dangerous menace. Biomolecules, 2020; 10(5):720; doi: 10.3390/biom10050720
3.
CastanheiraM, MendesRE, GalesAC. Global epidemiology and mechanisms of resistance of acinetobacter baumannii-calcoaceticus complex. Clin Infect Dis, 2023; 76(Suppl 2):S166–S178; doi: 10.1093/cid/ciad109
4.
WeinbergSE, VilledieuA, BagdasarianN, et al.Control and management of multidrug resistant Acinetobacter baumannii: A review of the evidence and proposal of novel approaches. Infect Prev Pract, 2020; 2(3):100077; doi: 10.1016/j.infpip.2020.100077
5.
AlmasaudiSB. Acinetobacter spp. as nosocomial pathogens: Epidemiology and resistance features. Saudi J Biol Sci, 2018; 25(3):586–596; doi: 10.1016/j.sjbs.2016.02.009
6.
LimaWG, Silva AlvesGC, SanchesC, et al.Carbapenem-resistant Acinetobacter baumannii in patients with burn injury: A systematic review and meta-analysis. Burns, 2019; 45(7):1495–1508; doi: 10.1016/j.burns.2019.07.006
7.
WeiZ, ZhaoL, YanJ, et al.Dynamic monitoring of neutrophil/lymphocyte ratio, APACHE II score, and SOFA score predict prognosis and drug resistance in patients with Acinetobacter baumannii-calcoaceticus complex bloodstream infection: A single-center retrospective study. Front Microbiol, 2024; 15:1296059; doi: 10.3389/fmicb.2024.1296059
8.
VahhabiA, HasaniA, RezaeeMA, et al.A plethora of carbapenem resistance in Acinetobacter baumannii: No end to a long insidious genetic journey. J Chemother, 2021; 33(3):137–155; doi: 10.1080/1120009X.2020.1847421
9.
DehbanipourR, GhalavandZ. Acinetobacter baumannii: Pathogenesis, virulence factors, novel therapeutic options and mechanisms of resistance to antimicrobial agents with emphasis on tigecycline. J Clin Pharm Ther, 2022; 47(11):1875–1884; doi: 10.1111/jcpt.13787
10.
NguyenM, JoshiSG. Carbapenem resistance in Acinetobacter baumannii, and their importance in hospital-acquired infections: A scientific review. J Appl Microbiol, 2021; 131(6):2715–2738; doi: 10.1111/jam.15130
11.
Tal-JasperR, KatzDE, AmramiN, et al.Clinical and epidemiological significance of carbapenem resistance in Acinetobacter baumannii infections. Antimicrob Agents Chemother, 2016; 60(5):3127–3131; doi: 10.1128/AAC.02656-15
12.
LeeCM, KimCJ, KimSE, et al.; Korea Infectious Diseases (KIND) Study Group. Risk factors for early mortality in patients with carbapenem-resistant Acinetobacter baumannii bacteraemia. J Glob Antimicrob Resist, 2022; 31:45–51; doi: 10.1016/j.jgar.2022.08.010
13.
AntunesLC, ViscaP, TownerKJ. Acinetobacter baumannii: Evolution of a global pathogen. Pathog Dis, 2014; 71(3):292–301; doi: 10.1111/2049-632X.12125
14.
ÇağlanE, NigizŞ, SancakB, et al.Resistance and heteroresistance to colistin among clinical isolates of Acinetobacter baumannii. Acta Microbiol Immunol Hung, 2020; 67(2):107–111; doi: 10.1556/030.66.2019.021
15.
KannianP, MahanathiP, AshwiniV, et al.Carbapenem-Resistant gram negative bacilli are predominantly multidrug or pan-drug resistant. Microb Drug Resist, 2021; 27(8):1057–1062; doi: 10.1089/mdr.2020.0294
16.
AminM, NavidifarT, ShooshtariFS, et al.Association between biofilm formation, structure, and the expression levels of genes related to biofilm formation and biofilm-specific resistance of Acinetobacter baumannii strains isolated from burn infection in Ahvaz, Iran. Infect Drug Resist, 2019; 12:3867–3881; doi: 10.2147/IDR.S228981
17.
KempfM, RolainJM. Emergence of resistance to carbapenems in Acinetobacter baumannii in Europe: Clinical impact and therapeutic options. Int J Antimicrob Agents, 2012; 39(2):105–114; doi: 10.1016/j.ijantimicag.2011.10.004
18.
GuY, ZhangW, LeiJ, et al.Molecular epidemiology and carbapenem resistance characteristics of Acinetobacter baumannii causing bloodstream infection from 2009 to 2018 in northwest China. Front Microbiol, 2022; 13:983963; doi: 10.3389/fmicb.2022.983963
19.
WuD, HuangY, DingJ, et al.Impact of carbapenem-resistant Acinetobacter baumannii infections on acute pancreatitis patients. Pancreatology, 2022; 22(2):194–199; doi: 10.1016/j.pan.2021.12.004
20.
McConnellMJ, ActisL, PachonJ. Acinetobacter baumannii: Human infections, factors contributing to pathogenesis and animal models. FEMS Microbiol Rev, 2013; 37(2):130–155; doi: 10.1111/j.1574-6976.2012.00344.x
21.
WangM, EarleyM, ChenL, et al.; Multi-Drug Resistant Organism Network Investigators. Clinical outcomes and bacterial characteristics of carbapenem-resistant Klebsiella pneumoniae complex among patients from different global regions (CRACKLE-2): A prospective, multicentre, cohort study. Lancet Infect Dis, 2022; 22(3):401–412; doi: 10.1016/S1473-3099(21)00399-6
22.
FiroozehF, BakhshiF, DadashiM, et al.Detection of multidrug-resistant Acinetobacter baumannii from burn patients and healthcare workers in Iran. Acta Microbiol Immunol Hung, 2023; 70(1):22–28; doi: 10.1556/030.2023.01921
23.
WongD, NielsenTB, BonomoRA, et al.Clinical and pathophysiological overview of Acinetobacter infections: A century of challenges. Clin Microbiol Rev, 2017; 30(1):409–447; doi: 10.1128/CMR.00058-16
24.
AlidoostiY, MehravarF, Shirzad-AskiH, et al.Nosocomial carbapenem-drug resistant Acinetobacter baumannii, related factors and clinical outcomes in Northeast Iran. BMC Infect Dis, 2024; 24(1):1103; doi: 10.1186/s12879-024-09972-z
TacconelliE, CarraraE, SavoldiA, et al.; WHO Pathogens Priority List Working Group. Discovery, research, and development of new antibiotics: The WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis, 2018; 18(3):318–327; doi: 10.1016/S1473-3099(17)30753-3
27.
Castillo BejaranoJI, Llaca DiazJ, MeElOC, et al.Carbapenem-Resistant Acinetobacter baumannii infection in children from a third-level hospital in Mexico: Clinical characteristics and molecular epidemiology. J Pediatric Infect Dis Soc, 2023; 12(7):431–435; doi: 10.1093/jpids/piad046
28.
QinX, DingL, HaoM, et al.Antimicrobial resistance of clinical bacterial isolates in China: Current status and trends. JAC Antimicrob Resist, 2024; 6(2):dlae052; doi: 10.1093/jacamr/dlae052
29.
AyobamiO, WillrichN, SuwonoB, et al.The epidemiology of carbapenem-non-susceptible Acinetobacter species in Europe: Analysis of EARS-Net data from 2013 to 2017. Antimicrob Resist Infect Control, 2020; 9(1):89; doi: 10.1186/s13756-020-00750-5
30.
SaderHS, MendesRE, StreitJM, et al.Antimicrobial susceptibility of Gram-negative bacteria from intensive care unit and non-intensive care unit patients from United States hospitals (2018-2020). Diagn Microbiol Infect Dis, 2022; 102(1):115557; doi: 10.1016/j.diagmicrobio.2021.115557
31.
BartalC, RolstonKVI, NesherL. Carbapenem-resistant Acinetobacter baumannii: Colonization, infection and current treatment options. Infect Dis Ther, 2022; 11(2):683–694; doi: 10.1007/s40121-022-00597-w
32.
NingC, HuangG, ShenD, et al.Adverse clinical outcomes associated with multidrug-resistant organisms in patients with infected pancreatic necrosis. Pancreatology, 2019; 19(7):935–940; doi: 10.1016/j.pan.2019.09.008
33.
TianH, ChenL, WuX, et al.Infectious complications in severe acute pancreatitis: Pathogens, drug resistance, and status of nosocomial infection in a university-affiliated teaching hospital. Dig Dis Sci, 2020; 65(7):2079–2088; doi: 10.1007/s10620-019-05924-9
34.
DeshwalPR, FathimaR, AggarwalM, et al.A systematic review and meta-analysis for risk factor profiles in patients with resistant Acinetobacter baumannii infection relative to control patients. Int J Risk Saf Med, 2023; 34(4):337–355; doi: 10.3233/JRS-220037
35.
GuY, JiangY, ZhangW, et al.Risk factors and outcomes of bloodstream infections caused by Acinetobacter baumannii: A case-control study. Diagn Microbiol Infect Dis, 2021; 99(2):115229; doi: 10.1016/j.diagmicrobio.2020.115229
36.
AlrahmanyD, OmarAF, AlreesiA, et al.Acinetobacter baumannii infection-related mortality in hospitalized patients: Risk factors and potential targets for clinical and antimicrobial stewardship interventions. Antibiotics (Basel), 2022; 11(8):1086; doi: 10.3390/antibiotics11081086
37.
NiuT, XiaoT, GuoL, et al.Retrospective comparative analysis of risk factors and outcomes in patients with carbapenem-resistant Acinetobacter baumannii bloodstream infections: Cefoperazone-sulbactam associated with resistance and tigecycline increased the mortality. Infect Drug Resist, 2018; 11:2021–2030; doi: 10.2147/IDR.S169432
38.
LiuY, WangQ, ZhaoC, et al.Prospective multi-center evaluation on risk factors, clinical characteristics and outcomes due to carbapenem resistance in Acinetobacter baumannii complex bacteraemia: Experience from the Chinese Antimicrobial Resistance Surveillance of Nosocomial Infections (CARES) network. J Med Microbiol, 2020; 69(7):949–959; doi: 10.1099/jmm.0.001222
39.
LinMF, YangCM, LinCH, et al.Clinical features and molecular epidemiology of multidrug-resistant Acinetobacter calcoaceticus-A baumannii complex in a regional teaching hospital in Taiwan. Am J Infect Control, 2009; 37(9):e1–e3; doi: 10.1016/j.ajic.2009.03.008
40.
MaillardJY, PascoeM. Disinfectants and antiseptics: Mechanisms of action and resistance. Nat Rev Microbiol, 2024; 22(1):4–17; doi: 10.1038/s41579-023-00958-3
41.
AppanealHJ, LopesVV, LaPlanteKL, et al.Treatment, clinical outcomes, and predictors of mortality among a national cohort of admitted patients with Acinetobacter baumannii infection. Antimicrob Agents Chemother, 2022; 66(3):e0197521; doi: 10.1128/AAC.01975-21
42.
GirmeniaC, RossoliniGM, PiciocchiA, et al.; Gruppo Italiano Trapianto Midollo Osseo GITMO. Infections by carbapenem-resistant Klebsiella pneumoniae in SCT recipients: A nationwide retrospective survey from Italy. Bone Marrow Transplant, 2015; 50(2):282–288; doi: 10.1038/bmt.2014.231
43.
YangCH, SuPW, MoiSH, et al.Biofilm formation in Acinetobacter baumannii: Genotype-Phenotype correlation. Molecules, 2019; 24(10):1849; doi: 10.3390/molecules24101849
44.
ThatrimontrichaiA, TechatoC, DissaneevateS, et al.Risk factors and outcomes of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia in the neonate: A case-case-control study. J Infect Chemother, 2016; 22(7):444–449; doi: 10.1016/j.jiac.2016.03.013
45.
ZhangY, XuG, MiaoF, et al.Insights into the epidemiology, risk factors, and clinical outcomes of carbapenem-resistant Acinetobacter baumannii infections in critically ill children. Front Public Health, 2023; 11:1282413; doi: 10.3389/fpubh.2023.1282413
46.
LeeSO, KimNJ, ChoiSH, et al.Risk factors for acquisition of imipenem-resistant Acinetobacter baumannii: A case-control study. Antimicrob Agents Chemother, 2004; 48(1):224–228; doi: 10.1128/AAC.48.1.224-228.2004
47.
SultanAM, SeliemWA. Identifying risk factors for healthcare-associated infections caused by carbapenem-resistant acinetobacter baumannii in a neonatal intensive care unit. Sultan Qaboos Univ Med J, 2018; 18(1):e75–e80; doi: 10.18295/squmj.2018.18.01.012
48.
HeX, TangJ, HeS, et al.Analysis of risk factors and different treatments for infections caused by carbapenem-resistant Acinetobacter baumannii in Shaanxi, China. BMC Infect Dis, 2024; 24(1):1130; doi: 10.1186/s12879-024-10036-5
49.
FranzoneJP, MackowNA, van DuinD. Current treatment options for pneumonia caused by carbapenem-resistant Acinetobacter baumannii. Curr Opin Infect Dis, 2024; 37(2):137–143; doi: 10.1097/QCO.0000000000001001
50.
TammaPD, AitkenSL, BonomoRA, et al.Infectious diseases society of america guidance on the treatment of AmpC beta-Lactamase-Producing enterobacterales, carbapenem-resistant acinetobacter baumannii, and stenotrophomonas maltophilia infections. Clin Infect Dis, 2022; 74(12):2089–2114; doi: 10.1093/cid/ciab1013
51.
BredinS, CharpentierJ, MiraJP, et al.Impact of colonization with multidrug-resistant bacteria on the risk of ventilator-associated pneumonia in septic shock. J Crit Care, 2022; 71:154068; doi: 10.1016/j.jcrc.2022.154068
52.
ErshovaK, SavinI, KurdyumovaN, et al.Implementing an infection control and prevention program decreases the incidence of healthcare-associated infections and antibiotic resistance in a Russian neuro-ICU. Antimicrob Resist Infect Control, 2018; 7:94; doi: 10.1186/s13756-018-0383-4
53.
Vazquez GuillametC, KollefMH. Acinetobacter pneumonia: Improving outcomes with early identification and appropriate therapy. Clin Infect Dis, 2018; 67(9):1455–1462; doi: 10.1093/cid/ciy375
